3 impressive Aussie companies, how often should you invest & don’t listen to Michael Burry
Summary
This episode analyzes global reporting season, highlighting record index highs and strong earnings across the US, Europe, and Australia. The hosts deep-dive into Nick Scully, ResMed, and REA Group, discussing mixed outlooks and the impact of GLP-1 drugs. They also answer listener questions on dollar-cost averaging timing and new capital gains tax rules, concluding with a critique of Michael Burry’s persistent bearish predictions.
Topics discussed
Introduction and episode overview
Global market highs and reporting season context
Quickfire earnings: Pinnacle and Rio Tinto
Nick Scully: Great results, terrible outlook
ResMed: GLP-1 drugs and sleep apnea diagnosis
REA Group: Dominance despite flat listings
Portfolio strategy and market opportunities
Dollar cost averaging: Day and frequency myths
Budget changes: Inflation-indexed cost bases
Michael Burry: Predictions vs. market reality
Listen ad-free on Castria